Related Experiment Video
Updated: Feb 7, 2026
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Daily Physical Activity in Pulmonary Arterial Hypertension: Insights From a Multicenter Longitudinal Trial Using
Jasleen Minhas1, Haochang Shou2, Nadine Al-Naamani1
1Division of Pulmonary, Allergy and Critical Care, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.
Background:
Pulmonary arterial hypertension (PAH) is a progressive disease associated with high morbidity and mortality. Traditional assessments such as the 6-minute walk distance (6MWD) may not adequately capture daily physical activity or patient experience in real-world settings.
Research Question:
Among patients with PAH, do accelerometer-derived measures of daily physical activity reflect disease severity, functional status, and outcomes over time?
Study Design And Methods:
Pulmonary Hypertension and Anastrozole (PHANTOM), a multicenter randomized controlled trial of anastrozole in PAH, enrolled male patients and postmenopausal female patients with PAH at 7 centers in the United States. Patients completed 4 in-person study visits over 12 months. Participants wore hip-based accelerometers for 7 days at each visit. Mixed-effects models assessed associations between daily physical activity and demographic, clinical, echocardiographic, and environmental variables. Clinical outcomes included: 6MWD; health-related quality of life (HRQoL), assessed by using the emPHasis-10 questionnaire and the 36-item Short Form Health Survey; bone mineral density (BMD); and time to clinical worsening (hospitalization, treatment escalation, or death). Cox models were used to examine associations between activity and time to clinical worsening.
Results:
Eighty-four participants were enrolled (mean age 61 years; 67% female). Device adherence was high across visits. Activity declined over time and was lower in patients with World Health Organization functional class III, worse right ventricular function, and connective tissue disease-associated PAH. Lower daily activity was associated with worse HRQoL, worse baseline 6MWD, and worse baseline femoral/hip BMD. Lower baseline activity was associated with increased risk of clinical worsening (hazard ratio, 1.06 per hour/week less active; P < .01).
Interpretation:
Our results suggest that accelerometer-derived physical activity reflects disease severity and is associated with HRQoL, BMD, and clinical worsening in PAH. These metrics may offer a dynamic, patient-centered complement to traditional assessments.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...